ClinicalTrials.gg
CompletedNCT06846710Updated Nov 4, 2026

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118

A Phase 1 interventional study of HS-20118 and HS-20118 placebo in Psoriasis, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

Updated Nov 4, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited — 7 open to participants now, 7 under way, 2 of them phase 3. Psoriasis · Hansoh Pharmaceutical Group Company Limited.

Enrollment
9th of 10
60 · median 131
Started
2025
with 5 others
Phase 1
4 of 10
1 open now
Registered
5th of 10
by date

Among the 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited, this one is the 9th largest by enrollment, is one of 6 that started in 2025, is one of 4 in phase 1, and was the 5th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

7 of the 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited, or all of them as a file.
02

Study summary

The study will be conducted in 2 parts (SAD for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 after a single oral dose in healthy participants.

Part 2 is a multi-center, randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability, immunogenicity, PK, and PD of HS-20118 after multiple oral doses in patients with moderate to severe plaque psoriasis .

Read the detailed description

The study will be conducted in 2 parts (SAD for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 after a single oral dose in healthy participants.

Part 1 will consist of 5 cohorts, i.e., X1 mg, X2 mg, X3 mg, X4 mg, and X5 mg dose cohorts (each cohort will include 3 participants to receive placebo). There will be no restriction on the male-to-female ratio. Each cohort will include 12 participants (HS-20118:placebo = 9:3), with a total of 60 participants. Participants will undergo PK blood sampling, ADA blood sampling, PD blood sampling and safety examinations during the study.

Part 2 is a multi-center, randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability, immunogenicity, PK, and PD of HS-20118 after multiple oral doses in patients with moderate to severe plaque psoriasis.

Part 2 will tentatively consist of 6 cohorts ( HS-20118 vs placebo = 9:3), i.e., (1) A1 mg, (2) A2 mg, (3) A3 mg, (4) A4 mg, (5) A5 mg, (6) A6 mg. Each cohort will include 12 participants (HS-20118:placebo = 9:3), with a total of 72 participants. There will be no restriction on the male-to-female ratio. Participants will undergo PK blood sampling, ADA blood sampling, PD blood sampling and safety examinations during the study.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For the SAD study:

  1. Healthy adults aged 18-45 years (inclusive) at the time of signing the form;
  2. Male participants weighing ≥ 50 kg and female participants weighing ≥ 45 kg, both ≤ 110 kg; (weight/square of height (kg/m2)) within the range of 18-28 kg/m2 (inclusive);
  3. Normal results or abnormal results but without clinical significance in comprehensive examinations, including general physical examination, vital signs, laboratory tests, 12-lead , abdominal color Doppler ultrasound, and chest X-ray from the frontal and lateral position ;

For the MAD study:

  1. Male or female participants aged 18-65 years (inclusive) at the time of signing the informed consent form;
  2. Male participants weighing ≥ 50 kg and female participants weighing ≥ 45 kg, both ≤ 110 kg;
  3. Chronic plaque psoriasis for at least 6 months with or without psoriatic arthritis;

Exclusion criteria

Exclusion Criteria:

For the SAD study:

  1. Participants with immune-related diseases and medical history at screening;
  2. Participants with a history of drug or other allergies who are considered by the investigator to be at high risk for participating in this study, or who may be allergic to the medicinal product or any component of the investigational medicinal product as judged by the investigator;
  3. History of drug abuse within the past 5 years or use of illicit drugs within 3 months before the study; or positive for urine drug screening;

For the MAD study:

  1. Guttate psoriasis, pustular psoriasis, erythrodermic psoriasis, drug-induced psoriasis, or other diseases that affect the treatment results;
  2. Current use of illicit drugs or prior use of illicit drugs within the specific time periods;
  3. Known history of recurrent or chronic infections, or prior history of chronic or recurrent infections, including but not limited to: chronic renal infection, chronic chest infection (e.g., bronchiectasis), symptomatic urinary tract infection, and open, draining, or infected skin wounds; history of serious infections (e.g., sepsis, pneumonia, and pyelonephritis), or hospitalization or treatment with intravenous antibiotics for infections within 2 months before screening;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    HS-20118

    Single and multiple ascending doses of HS-20118 orally

    Drug: HS-20118

  • Placebo comparator
    placebo

    Single and multiple ascending doses of HS-20118-matched placebo orally

    Other: HS-20118 placebo

Interventions

  • Single and multiple ascending doses of HS-20118 orally

  • OtherHS-20118 placebo

    Single and multiple ascending doses of HS-20118-matched placebo orally

06

What researchers measure

Primary outcomes

  1. Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation

    adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  2. Number of participants with abnormalities of physical examination

    Physical examination includes skin, mucous membranes, lymph nodes, head, neck, chest, abdomen, and spine/limbs, etc.

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  3. Number of participants with abnormalities of vital signs

    Vital sign measured include body temperature, blood pressure, pulse, and respiratory rate.

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  4. Number of participants with clinical laboratory abnormalities

    Clinical laboratory tests include blood biochemistry test, hematology test, urinalysis, coagulation function test, etc.

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  5. Number of participants with abnormalities of electrocardiogram (ECG) parameters

    ECG parameters include heart rate, PR interval, RR interval, QRS duration, QTcF interval.

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

Secondary outcomes

  1. Cmax

    Maximum plasma concentration

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  2. Tmax

    Time to reach Cmax

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  3. AUC

    Area under the plasma concentration-time curve

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  4. t½

    Terminal half-life

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  5. CL/F

    Apparent clearance

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  6. Vd/F

    Apparent volume of distribution

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  7. Rac

    Accumulation ratio

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  8. Incidence of Anti-drug antibody (ADA)

    Anti-drug antibody (ADA)

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  9. Proportions of psoriasis area and severity index (PASI) 75

    The PASI assessment will assess erythema, thickening (plaque evaluation, induration), and scaling (desquamation) on the head, trunk, upper limbs, and lower limbs, respectively

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  10. Proportions of psoriasis area and severity index (PASI) 90

    The PASI assessment will assess erythema, thickening (plaque evaluation, induration), and scaling (desquamation) on the head, trunk, upper limbs, and lower limbs, respectively

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  11. Proportions of psoriasis area and severity index (PASI) 100

    The PASI assessment will assess erythema, thickening (plaque evaluation, induration), and scaling (desquamation) on the head, trunk, upper limbs, and lower limbs, respectively

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  12. Proportions of Investigator's Global Assessment (IGA) 0/1

    The investigator scores each of infiltration/hypertrophy (I), erythema (E), and scaling (S) as a whole

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  13. Proportions of Investigator's Global Assessment (IGA) 0

    The investigator scores each of infiltration/hypertrophy (I), erythema (E), and scaling (S) as a whole

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  14. Change from baseline in psoriasis area and severity index (PASI) total score

    The PASI assessment will assess erythema, thickening (plaque evaluation, induration), and scaling (desquamation) on the head, trunk, upper limbs, and lower limbs, respectively

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  15. Change from baseline in body surface area (BSA)

    The total BSA affected by plaque psoriasis is estimated based on the percent area affected, including head, trunk, upper extremities, and lower extremities

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

  16. Change from baseline in dermatology life quality index (DLQI)

    The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne, and viral warts

    Time frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

07

Study locations

9 sites
  • Kinetic Clinical Research
    Anaheim, California 92806, United States
  • Clinitiative - Floridian Clinical Research, LLC
    Miami Lakes, Florida 33016, United States
  • NuLine Clinical Trial Center (Network)
    Pompano Beach, Florida 33060, United States
  • Pacific Clinical Research Network (PCRN), Auckland
    Takapuna, Auckland 0622, New Zealand
  • Pacific Clinical Research Network (PCRN), Christchurch
    Christchurch, Christchurch 8013, New Zealand
  • Momentum Clinical Research, Dunedin
    Dunedin, Dunedin 9016, New Zealand
  • Momentum Clinical Research, Pukekohe
    Pukekohe, Pukekohe 2120, New Zealand
  • Pacific Clinical Research Network (PCRN), Wellington
    Upper Hutt, Upper Hutt 5018, New Zealand
  • Momentum Clinical Research, Wellington
    Mount Cook, Wellington Region 6021, New Zealand
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jul 2026, 14 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 14 months is above that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Jul 2026 and completion Feb 2027 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2025
First posted
Feb 26, 2025
StartActual
May 2, 2025
Primary completionActual
Jul 14, 2026was Oct 2026
CompletionActual
Jul 14, 2026was Feb 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 4, 2026
Primary completion
Oct 30, 2026→Jul 14, 2026 (actual)
Nov 4, 2026
Study completion
Feb 28, 2027→Jul 14, 2026 (actual)
Nov 4, 2026
Enrollment
132 (estimated)→60 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Completed
    Primary completion Oct 30, 2026→Jul 14, 2026 (now actual)
    Study completion Feb 28, 2027→Jul 14, 2026 (now actual)
    Enrollment 132 (estimated)→60 (actual)
    + 4 other changes: verification date, registry dates, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06846710
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
May 2, 2025
Primary completion
Jul 14, 2026
Completion
Jul 14, 2026
Last update
Nov 4, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-20118

Start the discussion